Seikagaku (4548) · InitiativeAdvanced
Exclusive U.S. Sales Agreement for Visco-3
First written in FY2017-Q2. 1 of 3 entries say "Restated". Latest entry: FY2017.
3entries
2years
0from disclosures
How it moved
Same theme, other companies
Exclusive U.S. Sales Agreement for Visco-3A theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2017AdvancedAnnual report
「In November 2016, we also entered into an exclusive U.S. sales agreement with the company for VISCO-3, a joint-function improvement product administered in 3 doses.」
The disclosure describes the execution of an exclusive U.S. sales agreement for VISCO-3 and progress in establishing a U.S. product lineup with different dosing frequencies. - FY2017-Q3RestatedAnnual report
「Exclusive U.S. sales rights for VISCO-3. Contract term: 10 years from the contract date, with Zimmer Biomet Holdings, Inc. holding an option to renew for an additional 5 years」
The exclusive U.S. sales agreement with Zimmer Biomet for VISCO-3, the 10-year contract term and the 5-year renewal option are reiterated. - FY2017-Q2First statedAnnual report
「Exclusive U.S. sales rights for VISCO-3. Contract term: 10 years from the contract date, with Zimmer Biomet Holdings, Inc. holding an option to renew for an additional 5 years」
The disclosure states that an exclusive U.S. sales agreement for VISCO-3 was entered into with Zimmer Biomet Holdings, Inc. on 8 November 2016.